ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as primary and secondary outcome measures.

Topic Treatment-Resistant Depression
Compound Ketamine
Country United States of America
Visit trial
Status Recruiting
Results Published
Start date 04 July 2017
End date 31 December 2022
Chance of happening 100%
Phase Phase II Phase III
Design Open
Type Interventional
Generation First
Participants 400
Sex All
Age 21- 75
Therapy No

Trial Details

Patients with treatment resistant depression who meet all inclusion criteria and do not meet any exclusion criteria will be randomized to either electroconvulsive therapy (ECT) three times per week or ketamine infusion two times per week. Patients will answer questionnaires about their symptoms prior to treatments. The acute treatment phase of the study will last three to five weeks. Depending on response to treatment, some patients will be followed for an additional six months.

NCT Number NCT03113968

Sponsors & Collaborators

The Cleveland Clinic
This company doesn't have a full profile yet, it is linked to a clinical trial.

Patient-Centered Outcomes Research Institute
This company doesn't have a full profile yet, it is linked to a clinical trial.

Papers

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
This open-label, randomized trial (n=403) compared the effectiveness of iv ketamine (35mg/70kg, 6x, 3w) and electroconvulsive therapy (ECT) in treating treatment-resistant major depression (TRD). The results showed that 55.4% of patients in the ketamine group and 41.2% in the ECT group responded to the treatment, indicating ketamine was noninferior to ECT. ECT was associated with a temporary decrease in memory recall, while ketamine was associated with dissociation. Both treatments had similar improvements in patient-reported quality of life, with ECT having musculoskeletal adverse effects.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.